The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (N) and relatlimab (R) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).
 
Isabella Glitza
Honoraria - Amgen
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Leal Therapeutics; Midatech Pharma; Novartis; Sintetica
Speakers' Bureau - Array BioPharma
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst)
 
Suzanne Phillips
No Relationships to Disclose
 
Ida John
No Relationships to Disclose
 
Roland Bassett
No Relationships to Disclose
 
Michelle Rohlfs
No Relationships to Disclose
 
Jessie Richard
No Relationships to Disclose
 
Masood Iqbal
No Relationships to Disclose
 
Ian McCutcheon
No Relationships to Disclose
 
Sherise Ferguson
No Relationships to Disclose
 
Jeffrey Weinberg
Travel, Accommodations, Expenses - GT Medical Technologies
 
Golnaz Morad
No Relationships to Disclose
 
Adi Diab
Honoraria - Cullinan Oncology (Inst); CureVac; CytomX Therapeutics; Genesis Therapeutics; Idera (Inst); Lytix Biopharma (Inst); Memgen; Nektar (Inst); Pfizer; Regeneron; Teva
Consulting or Advisory Role - Celgene; CureVac; CytomX Therapeutics; Idera; Memgen therapeutics; Nektar; Pfizer (Inst); Regeneron
Research Funding - Apexigen (Inst); Celgene (Inst); Cullinan Oncology (Inst); Cullinan Oncology (Inst); Idera (Inst); Lytix Biopharma (Inst); Lytix Biopharma (Inst); Nektar (Inst); Pfizer (Inst)
 
Rodabe Amaria
Consulting or Advisory Role - Erasca, Inc; IO Biotech; KSQ Therapeutics; Obsidian Therapeutics; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Erasc (Inst); Genentech (Inst); iovance Biotherapeutics (Inst); KSQ Therapeutics (Inst); Novartis (Inst); Obsidian Therapeutics (Inst); OnKure (Inst); Regeneron (Inst)
 
Jennifer McQuade
Honoraria - Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - Bristol Myer Squibb; Roche Pharma AG
Travel, Accommodations, Expenses - Merck
 
Alexandra Ikeguchi
Research Funding - BioNTech SE (Inst); Immunocore (Inst); Merck (Inst); Regeneron (Inst)
 
Hussein Tawbi
Consulting or Advisory Role - Boxer Capital; Bristol-Myers Squibb; Genentech/Roche; IO Biotech; Iovance Biotherapeutics; Jazz Pharmaceuticals; Medicenna; Merck; Novartis; Pfizer; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst)
 
Elizabeth Burton
No Relationships to Disclose
 
Michael Davies
Consulting or Advisory Role - ABM; Apexigen; Array BioPharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; NanoString Technologies; Novartis; Nurix; Pfizer; Replimune
Research Funding - ABM (Inst); AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lead Pharma (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Pfizer (Inst); Sanofi (Inst)